HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pollution Protection, Blue Light Defense Among Cosmetic Tests In High Demand

This article was originally published in The Rose Sheet

Executive Summary

Craig Weiss, president of Consumer Product Testing Company, discussed trending cosmetics claims and testing that can be used to support them, as well as “claims that perhaps should not be made,” at ICMAD’s regulatory workshop in May.

You may also be interested in...

NAD: Sea & Ski Sunscreens May Go ‘Beyond UV,’ But Not To Infrared Zone

Cross Brands Manufacturing’s stingily hand-picked in vitro test results for Sea & Ski sunscreens do not demonstrate a clear, consumer-relevant infrared protection capability, let alone show that IR defense translates to meaningful skin-health benefits, according to the National Advertising Division’s Sept. 7 decision.

Whole Foods ‘Hypoallergenic’ Litigation To Test ‘Sensitizer’ Definition, Consumer Perceptions

A California federal judge has granted Whole Foods Market, Inc.’s motion to dismiss itself, all but one affiliate, and a number of plaintiff claims in the putative class action, but the core issue of contention – whether Whole Foods-branded “hypoallergenic” offerings are falsely labeled – remains to be litigated.

SPF Fraud Cases Hard To Shake, Could Shine Light On FDA Protocol Problems

As SPF defendants’ dismissal motions continue to be shot down in federal courts, it increasingly seems that their SPF claims and the radically different test results alleged by plaintiffs will have to be subjected to rigorous analysis and expert opinion, undertakings that could shine light on inherent problems with FDA’s testing protocol rather than overt moves by companies to inflate the protective capacity of their products.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts